[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626870":3},{"organization":4,"outcomesModule":7,"designInfo":67,"detailedDescription":11,"studyPopulation":11,"armGroups":76,"interventions":89,"overallOfficials":100,"centralContacts":104,"locations":110,"responsibleParty":319,"collaborators":11,"id":321,"slug":11,"hasResults":322,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":11,"eligibilityCriteria":326,"healthyVolunteers":322,"sex":327,"minAge":328,"maxAge":329,"enrollmentInfo":330,"targetDuration":11,"studyType":333,"phases":334,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":113,"whyStopped":11,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":352},{"fullName":5,"class":6},"Amgen","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) at Week 52",null,"Baseline and Week 52",{"measure":14,"description":11,"timeFrame":12},"Percent Change from Baseline in Body Weight at Week 52",[16,18,20,23,25,28,30,33,35,37,39,41,43,45,47,49,51,53,55,57,59,61,64],{"measure":17,"description":11,"timeFrame":12},"Number of Participants Achieving ≥ 30% Reduction from Baseline in Liver Fat Content (LFC) by MRI at Week 52",{"measure":19,"description":11,"timeFrame":12},"Percent Change from Baseline in Visceral Adipose Tissue (VAT) Volume by MRI at Week 52",{"measure":21,"description":11,"timeFrame":22},"Number of Participants Achieving \u003C 5% LFC by MRI at Week 52","Week 52",{"measure":24,"description":11,"timeFrame":12},"Change from Baseline in LFC by MRI at Week 52",{"measure":26,"description":11,"timeFrame":27},"Percent Change from Baseline in LFC by MRI at Week 24","Baseline and Week 24",{"measure":29,"description":11,"timeFrame":27},"Change from Baseline in LFC by MRI at Week 24",{"measure":31,"description":11,"timeFrame":32},"Percent Change from Baseline in Thigh Muscle Volume by MRI at Week 24 and Week 52","Baseline, Week 24, and 52",{"measure":34,"description":11,"timeFrame":32},"Percent Change from Baseline in Thigh Muscle Fat Fraction by MRI at Week 24 and Week 52",{"measure":36,"description":11,"timeFrame":32},"Percent Change from Baseline in Thigh Intermuscular and Intramuscular Fat Volume by MRI at Week 24 and Week 52",{"measure":38,"description":11,"timeFrame":12},"Percent Change from Baseline in Abdominal Subcutaneous Adipose Tissue (ASAT) Volume by MRI at Week 52",{"measure":40,"description":11,"timeFrame":27},"Percent Change from Baseline in VAT Volume by MRI at Week 24",{"measure":42,"description":11,"timeFrame":27},"Percent Change from Baseline in ASAT Volume by MRI at Week 24",{"measure":44,"description":11,"timeFrame":12},"Change from Baseline in Waist Circumference at Week 52",{"measure":46,"description":11,"timeFrame":12},"Change from Baseline in Waist-to-height Ratio at Week 52",{"measure":48,"description":11,"timeFrame":12},"Change from Baseline in Aspartate Aminotransferase (AST) at Week 52",{"measure":50,"description":11,"timeFrame":12},"Change from Baseline in Alanine Aminotransferase (ALT) at Week 52",{"measure":52,"description":11,"timeFrame":12},"Change from Baseline in Gamma Glutamyl Transferase (GGT) at Week 52",{"measure":54,"description":11,"timeFrame":12},"Change from Baseline in Hemoglobin A1c (HbA1c) at Week 52",{"measure":56,"description":11,"timeFrame":12},"Change from Baseline in Fasting Glucose at Week 52",{"measure":58,"description":11,"timeFrame":12},"Percent Change from Baseline in Fasting Insulin at Week 52",{"measure":60,"description":11,"timeFrame":22},"Plasma Concentration of Maridebart Cafraglutide at Week 52",{"measure":62,"description":11,"timeFrame":63},"Number of Participants Experiencing Treatment-emergent adverse events (TEAEs)","From first dose to end of trial (up to approximately 65 weeks)",{"measure":65,"description":11,"timeFrame":66},"Number of Participants Experiencing Serious AEs (SAEs)","From screening to end of trial (up to approximately 69 weeks)",{"allocation":68,"interventionModel":69,"interventionModelDescription":11,"primaryPurpose":70,"observationalModel":11,"timePerspective":11,"maskingInfo":71},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":72,"maskingDescription":11,"whoMasked":73},"DOUBLE",[74,75],"PARTICIPANT","INVESTIGATOR",[77,83],{"label":78,"type":79,"description":80,"interventionNames":81},"Maridebart Cafraglutide","EXPERIMENTAL","Participants will receive maridebart cafraglutide as a subcutaneous (SC) injection every 4 weeks (Q4W) for 52 weeks.",[82],"Drug: Maridebart cafraglutide",{"label":84,"type":85,"description":86,"interventionNames":87},"Placebo","PLACEBO_COMPARATOR","Participants will receive placebo as a SC injection Q4W for 52 weeks.",[88],"Drug: Placebo",[90,97],{"type":91,"name":92,"description":93,"armGroupLabels":94,"otherNames":95},"DRUG","Maridebart cafraglutide","Maridebart cafraglutide will be administered as a SC injection.",[78],[96],"AMG 133",{"type":91,"name":84,"description":98,"armGroupLabels":99,"otherNames":11},"Placebo will be administered as a SC injection.",[84],[101],{"name":102,"affiliation":5,"role":103},"MD","STUDY_DIRECTOR",[105],{"name":106,"role":107,"phone":108,"phoneExt":11,"email":109},"Amgen Call Center","CONTACT","866-572-6436","medinfo@amgen.com",[111,125,134,143,153,162,171,180,190,199,204,214,224,234,244,254,259,268,277,286,295,304,313],{"facility":112,"status":113,"city":114,"state":115,"zip":116,"country":117,"countryCode":118,"cosmosGeoPoint":119,"geoPoint":124,"contacts":11},"Arizona Clinical Trials","RECRUITING","Chandler","Arizona","85224","United States","US",{"type":120,"coordinates":121},"Point",[122,123],-111.84125,33.30616,{"lat":123,"lon":122},{"facility":126,"status":113,"city":127,"state":115,"zip":128,"country":117,"countryCode":118,"cosmosGeoPoint":129,"geoPoint":133,"contacts":11},"Medical Advancement Centers of Arizona","Phoenix","85044",{"type":120,"coordinates":130},[131,132],-112.07404,33.44838,{"lat":132,"lon":131},{"facility":135,"status":113,"city":136,"state":115,"zip":137,"country":117,"countryCode":118,"cosmosGeoPoint":138,"geoPoint":142,"contacts":11},"Del Sol Research Management","Tucson","85715",{"type":120,"coordinates":139},[140,141],-110.92648,32.22174,{"lat":141,"lon":140},{"facility":144,"status":113,"city":145,"state":146,"zip":147,"country":117,"countryCode":118,"cosmosGeoPoint":148,"geoPoint":152,"contacts":11},"San Fernando Valley Health Institute","Canoga Park","California","91304",{"type":120,"coordinates":149},[150,151],-118.59814,34.20112,{"lat":151,"lon":150},{"facility":154,"status":113,"city":155,"state":146,"zip":156,"country":117,"countryCode":118,"cosmosGeoPoint":157,"geoPoint":161,"contacts":11},"Gastroenterology and Liver Institute","Escondido","92025",{"type":120,"coordinates":158},[159,160],-117.08642,33.11921,{"lat":160,"lon":159},{"facility":163,"status":113,"city":164,"state":146,"zip":165,"country":117,"countryCode":118,"cosmosGeoPoint":166,"geoPoint":170,"contacts":11},"Inland Empire Liver Foundation","Rialto","92377",{"type":120,"coordinates":167},[168,169],-117.37032,34.1064,{"lat":169,"lon":168},{"facility":172,"status":113,"city":173,"state":146,"zip":174,"country":117,"countryCode":118,"cosmosGeoPoint":175,"geoPoint":179,"contacts":11},"Apex Clinical Research","San Diego","92120",{"type":120,"coordinates":176},[177,178],-117.16472,32.71571,{"lat":178,"lon":177},{"facility":181,"status":113,"city":182,"state":183,"zip":184,"country":117,"countryCode":118,"cosmosGeoPoint":185,"geoPoint":189,"contacts":11},"University of Florida College of Medicine-Jacksonville","Gainesville","Florida","32610",{"type":120,"coordinates":186},[187,188],-82.32483,29.65163,{"lat":188,"lon":187},{"facility":191,"status":113,"city":192,"state":183,"zip":193,"country":117,"countryCode":118,"cosmosGeoPoint":194,"geoPoint":198,"contacts":11},"Floridian Clinical Research LLC","Miami Lakes","33016",{"type":120,"coordinates":195},[196,197],-80.30866,25.90871,{"lat":197,"lon":196},{"facility":200,"status":113,"city":192,"state":183,"zip":193,"country":117,"countryCode":118,"cosmosGeoPoint":201,"geoPoint":203,"contacts":11},"Indago Research and Health Center",{"type":120,"coordinates":202},[196,197],{"lat":197,"lon":196},{"facility":205,"status":113,"city":206,"state":207,"zip":208,"country":117,"countryCode":118,"cosmosGeoPoint":209,"geoPoint":213,"contacts":11},"Gastrointestinal Specialists- Louisiana Research Center- Highland","Shreveport","Louisiana","71105",{"type":120,"coordinates":210},[211,212],-93.75018,32.52515,{"lat":212,"lon":211},{"facility":215,"status":113,"city":216,"state":217,"zip":218,"country":117,"countryCode":118,"cosmosGeoPoint":219,"geoPoint":223,"contacts":11},"Woodholme Gastroenterology Associates - Glen Burnie","Glen Burnie","Maryland","21061",{"type":120,"coordinates":220},[221,222],-76.62469,39.16261,{"lat":222,"lon":221},{"facility":225,"status":113,"city":226,"state":227,"zip":228,"country":117,"countryCode":118,"cosmosGeoPoint":229,"geoPoint":233,"contacts":11},"Alliance for Multispecialty Research - Kansas City","Kansas City","Missouri","64114",{"type":120,"coordinates":230},[231,232],-94.57857,39.09973,{"lat":232,"lon":231},{"facility":235,"status":113,"city":236,"state":237,"zip":238,"country":117,"countryCode":118,"cosmosGeoPoint":239,"geoPoint":243,"contacts":11},"Excel Clinical Research","Las Vegas","Nevada","89109",{"type":120,"coordinates":240},[241,242],-115.13722,36.17497,{"lat":242,"lon":241},{"facility":245,"status":113,"city":246,"state":247,"zip":248,"country":117,"countryCode":118,"cosmosGeoPoint":249,"geoPoint":253,"contacts":11},"Bellaire Clinical Research","Bellaire","Texas","77401",{"type":120,"coordinates":250},[251,252],-95.45883,29.70579,{"lat":252,"lon":251},{"facility":255,"status":113,"city":246,"state":247,"zip":248,"country":117,"countryCode":118,"cosmosGeoPoint":256,"geoPoint":258,"contacts":11},"Juno Research LLC",{"type":120,"coordinates":257},[251,252],{"lat":252,"lon":251},{"facility":260,"status":113,"city":261,"state":247,"zip":262,"country":117,"countryCode":118,"cosmosGeoPoint":263,"geoPoint":267,"contacts":11},"Pinnacle Clinical Research - Corpus Christi","Corpus Christi","78404",{"type":120,"coordinates":264},[265,266],-97.39638,27.80058,{"lat":266,"lon":265},{"facility":269,"status":113,"city":270,"state":247,"zip":271,"country":117,"countryCode":118,"cosmosGeoPoint":272,"geoPoint":276,"contacts":11},"South Texas Research Institute","Edinburg","78539",{"type":120,"coordinates":273},[274,275],-98.16334,26.30174,{"lat":275,"lon":274},{"facility":278,"status":113,"city":279,"state":247,"zip":280,"country":117,"countryCode":118,"cosmosGeoPoint":281,"geoPoint":285,"contacts":11},"Houston Research Institute","Houston","77079",{"type":120,"coordinates":282},[283,284],-95.36327,29.76328,{"lat":284,"lon":283},{"facility":287,"status":113,"city":288,"state":247,"zip":289,"country":117,"countryCode":118,"cosmosGeoPoint":290,"geoPoint":294,"contacts":11},"Houston Research Institute - Pasadena","Pasadena","77505",{"type":120,"coordinates":291},[292,293],-95.2091,29.69106,{"lat":293,"lon":292},{"facility":296,"status":113,"city":297,"state":247,"zip":298,"country":117,"countryCode":118,"cosmosGeoPoint":299,"geoPoint":303,"contacts":11},"McAllen Research","Pharr","78557",{"type":120,"coordinates":300},[301,302],-98.18362,26.1948,{"lat":302,"lon":301},{"facility":305,"status":113,"city":306,"state":247,"zip":307,"country":117,"countryCode":118,"cosmosGeoPoint":308,"geoPoint":312,"contacts":11},"American Research Corporation at the Texas Liver Institute","San Antonio","78215",{"type":120,"coordinates":309},[310,311],-98.49363,29.42412,{"lat":311,"lon":310},{"facility":314,"status":113,"city":306,"state":247,"zip":315,"country":117,"countryCode":118,"cosmosGeoPoint":316,"geoPoint":318,"contacts":11},"Pinnacle Clinical Research","78229",{"type":120,"coordinates":317},[310,311],{"lat":311,"lon":310},{"type":320,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100626870",false,"NCT07441252","A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight","Phase 2b Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Body Mass index (BMI) ≥ 27 kg\u002Fm\\^2 to ≤ 40 kg\u002Fm\\^2 at screening.\n* For participants with type 2 diabetes mellitus (T2DM) at screening:\n* HbA1c ≤ 9.5% (80 mmol\u002Fmol) at screening.\n* Treated with diet and exercise alone and\u002For a stable treatment with metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, or combination.\n* Liver Controlled Attenuation Parameter (CAPTM) ≥ 300 dB\u002Fmeter via FibroScan® assessment.\n* Liver fat content ≥ 10% by MRI as determined by the central imaging vendor at screening.\n* MRI assessment should only be performed after all other eligibility has been confirmed whenever possible.\n* History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise.\n\nExclusion Criteria:\n\n* Recent or planned surgical\u002Fdevice-based obesity treatment (\\\u003C1 year).\n* History of malignancy within the past 5 years (exceptions apply).\n* Type 1 diabetes or non-type 2 diabetes mellitus (T2DM); unstable\u002Fsevere hypoglycemia.\n* Advanced diabetic retinopathy or macular edema.\n* History of pancreatitis (acute \\\u003C180 days or chronic).\n* History of medullary thyroid carcinoma (MTC) or MEN-2\n* Major cardiovascular event within 60 days (e.g., myocardial infarction \\[MI\\], stroke, coronary artery bypass graft \\[CABG\\]).\n* New York Heart Association (NYHA) Class IV heart failure.\n* Unstable psychiatric disorders within 2 years.\n* Significant liver disease other than metabolic dysfunction-associated steatotic liver disease (MASLD) (e.g., hepatitis, cirrhosis, hepatic decompensation).\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m\\^2 or on dialysis.\n* Patient Health Questionnaire-9 (PHQ-9) ≥ 15, or suicidal ideation\u002Fbehavior (Columbia-Suicide Severity Rating Scale \\[C-SSRS\\]).\n* Inability to undergo MRI scan (e.g., due to metal implant, claustrophobia, or body size limitations).","ALL","18 Years","99 Years",{"count":331,"type":332},180,"ESTIMATED","INTERVENTIONAL",[335],"PHASE2","The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.",[338],"Overweight or Obesity and Elevated Liver Fat",[340,341,342,96,92],"Obesity","Overweight","Elevated liver fat","2026-06-17",{"date":345,"type":346},"2026-06-18","ACTUAL",{"date":348,"type":346},"2026-03-05",{"date":350,"type":332},"2027-12-22",{"name":5,"class":6},23]